Long-term survival of a patient with a large adrenal primitive neuroectodermal tumor: A case report

Table 1 Clinical characteristic of patients with adrenal primitive neuroectodermal tumor (since 2000)

Case	Year of publication	Gender	Age (yr)	Side	Symptom (local pain)	Endocrinal examination and tumor marker	Largest diameter of tumor (cm)	Adjacent invasions or distant metastasis	Surgery	Adjuvant therapy	Outcome (mo)
1	2000	M	57	R	-	-	15	+	+	N/A	N/A
2	2002	F	16	L	N/A	N/A	N/A	N/A	+	N/A	N/A
3	2006	F	53	R	N/A	-	3	N/A	+	-	10
4	2006	F	25	L	+	N/A	15.2	+	+	N/A	N/A
5	2006	F	24	N/A	+	N/A	8.4	N/A	N/A	N/A	N/A
6	2010	M	30	R	N/A	-	12	+	+	Radiotherapy	8 (death)
7	2010	F	21	L	N/A	-	10	+	-	-	6 (death)
8	2010	F	24	L	N/A	-	9	-	+	Chemotherapy	13 (recurrence)
9	2010	M	22	L	N/A	-	17	+	+	Chemotherapy	Recurrence
10	2011	F	17	R	+	-	5	-	+	Chemotherapy + Radiotherapy	14
11	2013	F	37	L	+	High 24 h urine cortisol and low-dose dexamethasone test (+)	12	+	+	-	N/A
12	2014	F	37	L	+	-	12	+	+	Chemotherapy	5
13	2014	F	40	L		-	14.6	+	+	Chemotherapy	8
14	2016	F	25	R	+	-	21	-	+	Chemotherapy + Brachytherapy	37
15	2016	M	45	B	+	-	9.6	+	-	Chemotherapy	N/A
16	2016	F	48	L	+	-	13	-	+	-	53 (recurrence)

PNET: Primitive neuroectodermal tumor; M: Male; F: Female; R: Right; L: Left; B: Bilateral; N/A: Not applicable.

Table 2 Pathological findings of adrenal primitive neuroectodermal tumor in available cases

Case	CD99	NSE	Syn	CgA	Vimentin	Fil-1	Genetic analysis
1	Strong+	+	+	Faible+	N/A	N/A	t(11:22)(q24:q12)
2	N/A	N/A	N/A N/A	N/A	N/A	N/A	N/A
3	Strong+	+	+	N/A	-	N/A	N/A
4	N/A	N/A	N/A	N/A	N/A	N/A	N/A
5	N/A	N/A	N/A	N/A	N/A	N/A	N/A
6	++	-	-	-	-	N/A	N/A
7	++	-	-	-	+	N/A	N/A
8	+	+	-	-	+	N/A	N/A
9	+	-	(+/-)	+	-	N/A	N/A
10	+	N/A	N/A N/A	N/A	N/A	N/A	t(11:22)(q24:q12)
11	Strong+	N/A	N/A	N/A	N/A	Faible+	N/A
12	+	N/A	-	N/A	+	+	t(11:22)(q24:q12)
13	+	N/A	+	N/A	+	N/A	N/A
14	+	+	+	+	+	N/A	N/A
15	+	N/A	N/A N/A	N/A	N/A	N/A	N/A
16	+	N/A	N/A N/A	N/A	+	Faible+	t(11:22)(q24:q12)

NSE: Neuron-specific enolase; Syn: Synaptophysin; CgA: Chromogranin A; N/A: Not applicable.